FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims
This article was originally published in The Tan Sheet
Executive Summary
A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus
You may also be interested in...
Fraudulent Zika Claims Are CDER's Latest Extermination Target
CDER is on the lookout for companies seeking to capitalize off the Zika health crisis with fraudulent claims about their products’ ability to treat or prevent the disease, says Brad Price, acting director of the Division of Nonprescription Drugs and Health Fraud, Office of Compliance.
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.